Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277051 · ClinicalTrials.gov registry record · Phase 1
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT05277051: Active Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
NCT05277051 is a Phase 1 study of Neoplasms that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 152 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277051, a Phase 1 study of Neoplasms, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Conditions Studied
Interventions
- DRUG Dostarlimab
- DRUG GSK5764227
- DRUG Remzistotug
- DRUG Belrestotug
- DRUG Nelistotug
Study Locations (20)
Other
- GSK Investigational Site - Chengdu
- GSK Investigational Site - Jinan
- GSK Investigational Site - Shanghai
- GSK Investigational Site - Wuhan
- GSK Investigational Site - Dijon
- GSK Investigational Site - Lille
- GSK Investigational Site - Chiba
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Seoul
- GSK Investigational Site - Seoul
Texas
- GSK Investigational Site - Dallas
- GSK Investigational Site - San Antonio
Ontario
- GSK Investigational Site - Ottawa
- GSK Investigational Site - Toronto
California
- GSK Investigational Site - San Francisco
North Carolina
- GSK Investigational Site - Charlotte
Oklahoma
- GSK Investigational Site - Oklahoma City
Pennsylvania
- GSK Investigational Site - Philadelphia
Utah
- GSK Investigational Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What the registry record for NCT05277051 still lists
NCT05277051 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Dostarlimab is the first listed.
NCT05277051 names 20 study sites across 9 states, led by Other, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT05277051 about?
NCT05277051 is a clinical study titled "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors". This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been e...
What is the current status of trial NCT05277051?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2022-03-22. Estimated completion is 2027-08-31.
What conditions does trial NCT05277051 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT05277051?
The interventions under investigation include: Dostarlimab (DRUG), GSK5764227 (DRUG), Remzistotug (DRUG), Belrestotug (DRUG), Nelistotug (DRUG).
Who is sponsoring clinical trial NCT05277051?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277051 being conducted?
This trial has 20 study locations across California, North Carolina, Oklahoma, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05277051's enrollment target sits among peer trials
152 55th of 158 higher than 103 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI